We wish to inform you that Asterisk Lifesciences Ltd, UK, a wholly owned subsidiary of Bliss GVS Pharma Limited, has obtained marketing authorization from the Medicines & Healthcare products Regulatory Agency (MHRA) for Mesalazine 1g Suppositiories.

November 04, 2026 To To The Manager, Listing Department The General Manager, Listing Department National Stock Exchange of India Limited BSE Limited Plot no. C/1 G Block, Phiroze Jeejeebhoy Towers, Bandra-Kurla Complex, Bandra (East), Dalal Street, Mumbai- 400 051 Mumbai- 400 001 Symbol: BLISSGVS Scrip Code: 506197 Subject: Intimation under Regulations 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Grant of Marketing Authorisation from MHRA, UK for Mesalazine 1g Suppositories Dear Sir/Madam, Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), this is to inform you that Asterisk Lifesciences Ltd, UK a wholly owned subsidiary of Bliss GVS Pharma Limited, has obtained marketing authorization from the Medicines & Healthcare products Regulatory Agency (MHRA) for Mesalazine 1g Suppositories. Kindly take the above intimation on record. Yours faithfully, For Bliss GVS Pharma Limited Aditi H. Bhatt Company Secretary & Compliance Officer